摘要
目的:分析盐酸西替利嗪滴剂联合孟鲁司特钠在咳嗽变异性哮喘(CVA)患儿中的应用效果。方法:采用前瞻性分析研究法,对2019年1月-2021年1月惠州市第一人民医院收治的90例CVA患儿进行研究,采用随机数字表法将其分为观察组和对照组,各45例。两组均给予孟鲁司特钠咀嚼片治疗,观察组联合使用盐酸西替利嗪滴剂治疗。对两组治疗前后的用力肺活量(FVC)、第1秒用力呼气容积(FEV)、呼气峰值流速(PEF)、免疫球蛋白E(IgE)、白细胞介素-5(IL-5)、白细胞介素-10(IL-10)、外周血辅助性T细胞1(Th1)、外周血辅助性T细胞2(Th2)水平进行比较,并对两组咳嗽症状指标、临床症状缓解及胸片正常时间、临床疗效和不良反应发生情况进行比较。结果:与治疗前1 d相比,两组治疗后1 d的FVC、FEV、PEF、IL-10、Th1水平均升高,IgE、IL-5、Th2水平均降低(P<0.05);与对照组相比,观察组治疗后1 d的FVC、FEV、PEF、IL-10、Th1水平均升高,IgE、IL-5、Th2水平均降低(P<0.05)。观察组治疗后的日间咳嗽评分、夜间咳嗽评分均低于对照组,咳嗽缓解时间、咳嗽消失时间、高热消失时间、呼吸困难缓解时间、胸片结果正常时间均短于对照组(P<0.05)。与对照组的80.00%相比,观察组的临床总有效率为97.78%,差异有统计学意义(P<0.05)。观察组有3例(6.67%)服药后出现兴奋、瘙痒、激惹,对照组有4例(8.89%)服药后出现嗜睡、困倦,两组均无其他明显不良反应,两组不良反应发生率比较,差异无统计学意义(χ^(2)=1.689,P=0.080)。结论:盐酸西替利嗪滴剂联合孟鲁司特钠能够改善CVA患儿的肺功能和炎症反应,可提高机体免疫力,促进咳嗽及各临床症状的恢复,改善临床疗效,且无明显不良反应,安全性较佳。
Objective:To analyze the effect of Cetirizine Hydrochloride Drops combined with Montelukast Sodium in children with cough variant asthma(CVA).Method:By prospective analysis,90 children with cough variant asthma admitted to the First People’s Hospital of Huizhou from January 2019 to January 2021 were studied,they were divided into observation group and control group by random number table method,with 45 cases in each group.Both groups were treated with Montelukast Sodium Chewable Tablets,and the observation group was treated with Cetirizine Hydrochloride Drops.Forced vital capacity(FVC),forced expiratory volume in the first second(FEV),peak expiratory flow rate(PEF),immunoglobulin E(IgE),interleukin-5(IL-5),interleukin-10(IL-10),peripheral blood T helper cell 1(Th1),peripheral blood T helper cell 2(Th2)were compared between the two groups before and after treatment,and the cough symptoms and clinical indicators,the symptom relief and the chest X-ray normal time,clinical efficacy and adverse reactions after treatment of the two groups were compared.Result:Compared with 1 d before treatment,the levels of FVC,FEV,PEF,IL-10 and Th1 in both groups increased 1 d after treatment,while the levels of IgE,IL-5 and Th2 decreased(P<0.05);compared with the control group,the levels of FVC,FEV,PEF,IL-10 and Th1 in the observation group increased 1 d after treatment,while the levels of IgE,IL-5 and Th2 decreased(P<0.05).The scores of daytime cough and night cough in the observation group were lower than those in the control group after treatment,and the cough relief time,cough disappear time,high fever disappear time,dyspnea relief time and the normal time of chest X-ray results were shorter than those in the control group(P<0.05).Compared with 80.00%of the control group,the total clinical effective rate of the observation group was 97.78%,the difference was statistically significant(P<0.05).In the observation group,3 cases experienced excitement,itching,and irritation after taking the drug,and 4 cases in the control group developed drowsiness and drowsiness after taking the drug.There were 3 cases(6.67%)in the observation group,and 4 cases(8.89%)in the control group,who appeared drowsiness and drowsiness after taking medicine,there were no other obvious adverse reactions between the two groups,and there was no statistical significance in the incidence of adverse reactions between the two groups(χ^(2)=1.689,P=0.080).Conclusion:Cetirizine Hydrochloride Drops combined with Montelukast Sodium can improve the lung function and inflammatory response of children with cough variant asthma,improve immunity,promote the recovery of cough and various clinical symptoms and improve clinical efficacy,no obvious adverse reactions,better safety.
作者
黄春生
HUANG Chunsheng(The First People’s Hospital of Huizhou,Guangdong Province,Huizhou 516000,China)
出处
《中国医学创新》
CAS
2022年第25期9-13,共5页
Medical Innovation of China
基金
惠州市科技计划项目(202136000Y040039)。
关键词
咳嗽变异性哮喘
盐酸西替利嗪滴剂
孟鲁司特钠
肺功能
Cough variant asthma
Cetirizine Hydrochloride Drops
Montelukast Sodium
Lung function
